Amendments to the Claims:

1. (Currently amended) A process for the preparation of the α-crystal form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-[4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]benzamide comprising:

   a) carrying out an acid addition reaction using not more than 0.99 equivalents of methanesulfonic acid per 1 equivalent of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-[(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]benzamide, in a solvent selected from the group consisting of C_2-C_6 aliphatic alcohols and the mixtures thereof, optionally with the addition of a C_1-C_4 aliphatic alcohol;

   b) optionally adding a solvent selected from the group consisting of esters formed from a C_1-C_4 aliphatic alcohol and formic acid, acetic acid, or propionic acid;

   c) optionally inoculating the reaction mixture with the α-crystal form;

   d) stirring the reaction mixture for the time necessary for crystallization of the α-crystal form; and

   e) isolating the α-crystal form from the reaction mixture,

   wherein said α-crystal form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-[(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]benzamide isolated from the reaction mixture shows an X-ray powder diffraction pattern that is characterized by having peaks at 2θ angles of approximately: 4.9; 18.6; 19.1; 23.2 and 28.6°.

2. (Original) The process according to claim 1 in which the acid addition reaction is carried out using from 0.95 to 0.99 equivalents of methanesulfonic

acid per 1 equivalent of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-[(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl] benzamide.

3. (Previously presented) The process according to claim 1, in which the acid addition reaction is carried out in an alcohol selected from the group consisting of *n*-propyl alcohol, isopropyl alcohol, *n*-butyl alcohol, *tert*-butyl alcohol, and the mixtures thereof with ethyl alcohol.

4. (Previously presented) The process according to claim 1, in which the acid addition reaction is carried out in a mixture of solvents containing from 0 to 50% of ethyl alcohol and from 50 to 100% of n-propyl alcohol (v/v).

5. (Previously presented) The process according to claim 1 in which the acid addition reaction is carried out in the mixture of solvents containing from 0 to 50% of ethyl alcohol and from 50 to 100% of isopropyl alcohol (v/v).

6. (Previously presented) The process according to claims 1 in which the acid addition reaction is carried out in a mixture of solvents containing from 0 to 50% of ethyl alcohol and from 50 to 100% of n-butyl alcohol (v/v).

7. (Previously presented) The process according to claims 1 in which the acid addition reaction is carried out in a mixture of solvents containing from 0 to 50% of ethyl alcohol and from 50 to 100% of *tert*-butyl alcohol (v/v).

8. (Currently amended) A process for the preparation of the α-crystal form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-[4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]benzamide comprising:

   a) carrying out an acid addition reaction using 1 equivalent of methanesulfonic acid per 1 equivalent of 4-(4-methylpiperazin-1-

ylmethyl)-N-[4-methyl-3-[(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]benzamide in the ethyl alcohol, optionally with the addition of a C_1-C_4 aliphatic alcohol;

b) adding a solvent selected from the group consisting of esters formed from a C_1-C_4 aliphatic alcohol and formic acid, acetic acid, or propionic acid;

c) inoculating the reaction mixture with the α-crystal form;

d) stirring the reaction mixture for the time necessary for crystallization of the α-crystal form; and

e) isolating the α-crystal form from the reaction mixture,

wherein said α-crystal form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-[(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]benzamide isolated from the reaction mixture shows an X-ray powder diffraction pattern that is characterized by having peaks at 2θ angles of approximately: 4.9; 18.6; 19.1; 23.2 and 28.6°.

9. (Previously presented) The process according to claim 8 wherein said C_1-C_4 aliphatic alcohol is methyl alcohol or isopropyl alcohol, and the proportion of said C_1-C_4 aliphatic alcohol to other solvents present in the reaction mixture do not exceed 55% (v/v).

10. (Previously presented) The process according to claim 1 in which the acid addition reaction is carried out with stirring while maintaining the internal temperature of the reaction mixture within the range from room temperature to boiling temperature.

11-12. (Canceled)

13. (Currently amended) The process according to claim 1 in which said α-crystal form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-[(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]benzamide isolated from the reaction mixture shows an X-ray powder diffraction pattern that is characterized by having peaks of relative intensity over 20% at 2θ angles of approximately: 4.9, 10.5; 14.9; 16.5; 17.7; 18.1; 18.6; 19.1; 21.3; 21.6; 22.7; 23.2; 23.8; 24.9; 27.4; 28.0 and 28.6°, the relative intensity being determined with respect to the most intense peak by peak height, the peak height expressing a number of counts per second.

14-23. (Canceled).

24. (Previously presented) The process according to claim 2, in which the acid addition reaction is carried out in an alcohol selected from the group comprising *n*-propyl alcohol, isopropyl alcohol, *n*-butyl alcohol, *tert*-butyl alcohol and the mixtures thereof with ethyl alcohol.

25. (Previously presented) The process according to claim 2 in which the addition reaction is carried out in the mixture containing from 0 to 50% of ethyl alcohol and from 50 to 100% of n-propyl alcohol (v/v).

26-27. (Canceled)

28. (Currently amended) The process according to claims 2 in which said α-crystal form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-[(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]benzamide isolated from the reaction mixture shows an X-ray powder diffraction pattern that is characterized by having peaks at 2θ

angles of approximately: 4.9, 10.5; 14.9; 16.5; 17.7; 18.1; 18.6; 19.1; 21.3; 21.6; 22.7; 23.2; 23.8; 24.9; 27.4; 28.0 and 28.6°.

29. (Previously presented) The process according to claim 8 in which the acid addition reaction is carried out with stirring while maintaining the internal temperature of the reaction mixture within the range from room temperature to boiling temperature.

30-31. (Canceled)

32. (Currently amended) The process according to claim 8 in which said α-crystal form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-[(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]benzamide isolated from the reaction mixture shows an X-ray powder diffraction pattern that is characterized by having peaks of relative intensity over 20% at 2θ angles of approximately: 4.9, 10.5; 14.9; 16.5; 17.7; 18.1; 18.6; 19.1; 21.3; 21.6; 22.7; 23.2; 23.8; 24.9; 27.4; 28.0 and 28.6°, the relative intensity being determined with respect to the most intense peak by peak height, the peak height expressing a number of counts per second.

33-36. (Canceled)

37. (Previously presented) The process of claim 8 wherein said α-crystal form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-[(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]benzamide isolated from the reaction mixture contains not more than 2% w/w of the β-crystal form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-[(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]benzamide.

38. (Previously presented) The process of claim 37 wherein said α-crystal form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-[(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]benzamide isolated from the reaction mixture contains not more than 1% w/w of the β-crystal form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-[(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]benzamide.